ADC Therapeutics is a commercial, global leader and pioneer in the field of antibody-drug conjugates (ADCs). We have a fully integrated value chain with specialized capabilities unique to the lifecycle of ADCs including research, translational and chemistry, manufacturing and controls. Our robust pipeline is comprised of ADCs in clinical trials for both hematologic and solid tumor cancers. We have a strong, proven technology platform in highly potent PBD-based ADCs and we are expanding our reach to develop next-generation assets.
Our senior leaders are industry veterans with experience in both large pharmaceutical companies and biotechnology startups and our highly skilled global workforce is committed to transforming the lives of patients with cancer.
Our History
2011
ADC Therapeutics founded as a spin-off from Spirogen Ltd. which was founded in 2000 and was an early innovator in PBD-based ADC research
2015
ADC Therapeutics cofounder Chris Martin appointed CEO
2016
First patient enrolled in phase 1 clinical trial of lead investigational compound loncastuximab tesirine-lpyl, targeting CD19 in positive B-cell non-Hodgkin lymphoma
2019
First patient enrolled in phase 2 clinical trial of investigational compound camidanlumab tesirine, targeting CD25 in relapsed or refractory Hodgkin lymphoma
2020
Ron Squarer, former CEO of Array BioPharma, Inc. appointed Chairman of the Board
$267-million IPO with the NYSE ticker “ADCT”
Announced pivotal phase 2 clinical trial of CD19-targeted, lead investigational compound loncastuximab tesirine-lpyl
Biologics license application (BLA) submission for CD19-targeted, lead investigational compound loncastuximab tesirine-lpyl
Biologics license application (BLA) acceptance with priority review for CD19-targeted, lead investigational compound loncastuximab tesirine-lpyl
2021
CD19-targeted, lead investigational compound loncastuximab tesirine-lpyl receives FDA approval
2022
Industry veteran Ameet Mallik joins as CEO
2022
- May
Industry veteran Ameet Mallik joins as CEO
2021
- April
CD19-targeted, lead investigational compound
loncastuximab tesirine-lpyl receives FDA approval
2020
- November
Biologics license application (BLA) acceptance with
priority review for CD19-targeted, lead investigational
compound loncastuximab tesirine-lpyl - September
Biologics license application (BLA) submission for
CD19-targeted, lead investigational compound
loncastuximab tesirine-lpyl - June
Announced pivotal phase 2 clinical trial of
CD19-targeted, lead investigational compound
loncastuximab tesirine-lpyl - May
$267-million IPO with the NYSE ticker “ADCT”
- March
Ron Squarer, former CEO of Array BioPharma, Inc.
appointed Chairman of the Board
2019
- October
First patient enrolled in phase 2 clinical trial of
investigational compound camidanlumab tesirine,
targeting CD25 in relapsed or refractory Hodgkin
lymphoma
2016
- March
First patient enrolled in phase 1 clinical trial of lead
investigational compound loncastuximab tesirine-lpyl,
targeting CD19 in positive B-cell non-Hodgkin lymphoma
2015
- June
ADC Therapeutics cofounder Chris Martin appointed CEO
2011
- June
ADC Therapeutics founded as a spin-off from Spirogen
Ltd. which was founded in 2000 and was an early
innovator in PBD-based ADC research
ADC, antibody-drug conjugate; PBD, pyrrolobenzodiazepine.
Our Purpose
Our mission, vision, and values form the foundation of ADC Therapeutics and provide guidance for all future endeavors. These foundational pillars are also a meaningful expression of the company’s dedication to helping those with difficult-to-treat cancers.
Our Mission
We are confronting cancer with the full potential of our science, bringing unique, targeted therapies and hope to patients and their families.
Our Vision
We will transform what patients and their families can expect from cancer therapy.
Our Values
PATIENTS: Patients and their families are at the core of everything we do; they inspire our scientific creativity and innovation
CHARACTER: We are open, honest, trustworthy, and respectful in our words and actions
URGENCY: We operate with a sense of urgency in all that we do
PEOPLE: We encourage individuals to continually learn and grow so that everyone can work at their full potential
Our Leadership
and the Board of Directors
Partnering
At ADC Therapeutics, we are on a mission to confront cancer with the full potential of our science to bring unique, targeted therapies and hope to patients and their families. To help support this mission, we actively seek innovative collaborations and strategic business development opportunities.
To start the conversation about partnering with ADC Therapeutics, please contact us at partnering@adctherapeutics.com.
Charitable Contributions & Sponsorships
Charitable Contributions
ADC Therapeutics’ interactive portal accepts unsolicited requests for charitable contributions/donations. The Company will evaluate funding requests monthly for events/activities of registered 501(c)3 tax-exempt organizations engaged in a healthcare-related charitable purpose aligned with ADC Therapeutics’ mission and vision. Requests will also be reviewed for consistency with our corporate objectives and compliance policies. Applicants outside of the U.S. must qualify as a charitable organization within the country where they reside.
This interactive portal allows you to: 1) provide necessary information so ADCT may appropriately evaluate your request, and 2) track the status of your request.
If your request does not fall under this category, we also have portals to evaluate other funding types. See links below:
- Sponsorships/Corporate or State Memberships/Patient Advocacy Grants
- Continuing Medical Education (CME) Grants
- Investigator-Initiated Trials (IITs)
Sponsorships/Memberships/Non-CME Grants
ADC Therapeutics’ interactive portal accepts unsolicited requests for sponsorships, corporate memberships, and non-CME grants that are aligned with ADCT’s mission, vision, and corporate objectives, and are consistent with our compliance policies.
This interactive portal allows you to: 1) provide necessary information so ADCT may appropriately evaluate your request, and 2) track the status of your request.
If your request does not fall under one of the mentioned categories, one of our other portals may fit your funding request. See links below:
Responsibility
Environmental, Social & Governance Report 2021
At ADCT we are committed to improving the lives of those affected by cancer with our next-generation, targeted therapies. We are determined to carry out this mission in a responsible, ethical, and sustainable manner that reflects our values and mirrors the innovation of our science.
We are pleased to present our inaugural corporate responsibility report.
